Insulin Syringes Market by Syringe Size, Disease and End User: Global Opportunity Analysis and Industry Forecast, 2021-2030

1.1. Report description
1.2. Key market segments
1.3. Research methodology
1.3.1. Primary research
1.3.2. Secondary research
1.3.3. Analyst tools and models

2.1. Key findings of the study
2.3. CXO perspective

3.1. Market definition and scope
3.2. Top player positioning
3.2.1. Top investment pockets
3.3. Key forces shaping insulin syringes industry/market
3.4. Market dynamics
3.4.1.1. Rise in prevalence of Diabetes
3.4.1.2. Surge in healthcare expenditure
3.4.1.3. Surge in geriatric population
3.4.2. Restraints
3.4.2.1. High price of Insulin
3.4.2.2. Availability of alternative modes of insulin delivery
3.4.3. Opportunity
3.4.3.1. High growth potential in Developing Countries
3.4.4. Impact Analysis
3.5. Impact of Covid-19 on the market

4.1. Overview
4.1.1. Market size and forecast
4.2.3/10 cc syringe (0.3ml)
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast
4.2.3. Market analysis, by country
4.3.1/2 cc Syringe (0.5 ml)
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast
4.3.3. Market analysis, by country
4.4.1cc Syringe (1 ml)
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast
4.4.3. Market analysis, by country
4.5. Others
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast
4.5.3. Market analysis, by country

5.1. Overview
5.1.1. Market size and forecast
5.2. Type-1 Diabetes
5.2.1. Market analysis, by region
5.2.2. Market analysis, by country
5.3. Type-2 Diabetes
5.3.1. Market size and forecast
5.3.2. Market analysis, by country

6.1. Overview
6.1.1. Market size and forecast
6.2. Hospitals& Clinics
6.2.1. Market size and forecast
6.2.2. Market analysis, by country
6.3. Homecare Settings
6.3.1. Market size and forecast
6.3.2. Market analysis, by country
6.4. Others.
6.4.1. Market size and forecast
6.4.2. Market analysis, by country

7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trendsand opportunities
7.2.2. Market size and forecast, by country
7.2.3. Market size and forecast, by Syringe Size
7.2.4. Market size and forecast, by Disease
7.2.5. Market size and forecast, by end user
7.2.6. U.S.
7.2.6.1. U.S. Market size and forecast, by Syringe Size
7.2.6.2. U.S. Market size and forecast, by disease
7.2.6.3. U.S. Market size and forecast, by end user
7.2.7. Canada
7.2.7.1. Canada. Market size and forecast, by syringe size
7.2.7.2. Canada. Market size and forecast, by disease
7.2.7.3. Canada Market size and forecast, by end user
7.2.8. Mexico
7.2.8.1. Mexico Market size and forecast, by Syringe Size
7.2.8.2. Mexico. Market size and forecast, by disease
7.2.8.3. Mexico Market size and forecast, by end user
7.3. Europe
7.3.1. Key market trends and opportunities
7.3.2. Market size and forecast, by country
7.3.3. Market size and forecast, by Syringe Size
7.3.4. Market size and forecast, by Disease
7.3.5. Market size and forecast, by end user
7.3.6. Germany
7.3.6.1. Germany Market size and forecast, by syringe Size
7.3.6.2. Germany Market size and forecast, by disease
7.3.6.3. Germany Market size and forecast, by end user
7.3.7. France
7.3.7.1. France Market size and forecast, by Syringe Size
7.3.7.2. France Market size and forecast, by disease
7.3.7.3. France Market size and forecast, by end user
7.3.8. UK
7.3.8.1. UK Market size and forecast, by Syringe Size
7.3.8.2. UK Market size and forecast, by disease
7.3.8.3. UK Market size and forecast, by end user
7.3.9. Italy
7.3.9.1. Italy Market size and forecast, by Syringe Size
7.3.9.2. Italy Market size and forecast, by disease
7.3.9.3. Italy Market size and forecast, by end user
7.3.10. Spain
7.3.10.1. Spain Market size and forecast, by Syringe Size
7.3.10.2. Spain Market size and forecast, by disease
7.3.10.3. Spain Market size and forecast, by end user
7.3.11. Rest of Europe
7.3.11.1. Rest of Europe Market size and forecast, by Syringe Size
7.3.11.2. Rest of Europe Market size and forecast, by disease
7.3.11.3. Rest of Europe Market size and forecast, by end user
7.4. Asia-Pacific
7.4.1. Key market trendsand opportunities
7.4.2. Market size and forecast, by country
7.4.3. Market size and forecast, by Syringe Size
7.4.4. Market size and forecast, by disease
7.4.5. Market size and forecast, by end user
7.4.6. Japan
7.4.6.1. Japan Market size and forecast, by syringe Size
7.4.6.2. Japan Market size and forecast, by disease
7.4.6.3. Japan Market size and forecast, by end user
7.4.7. China
7.4.7.1. China Market size and forecast, by syringe Size
7.4.7.2. China Market size and forecast, by Disease
7.4.7.3. China Market size and forecast, by end user
7.4.8. Australia
7.4.8.1. Australia Market size and forecast, by Syringe Size
7.4.8.2. Australia Market size and forecast, by Disease
7.4.8.3. Australia Market size and forecast, by end user
7.4.9. India
7.4.9.1. India Market size and forecast, by Syringe Size
7.4.9.2. India Market size and forecast, by Disease
7.4.9.3. India Market size and forecast, by end user
7.4.10. South Korea
7.4.10.1. South Korea Market size and forecast, by Syringe Size
7.4.10.2. South Korea Market size and forecast, by Disease
7.4.10.3. South Korea Market size and forecast, by end user
7.4.11. Rest of Asia-Pacific
7.4.11.1. Rest of Asia-Pacific Market size and forecast, by Syringe Size
7.4.11.2. Rest of Asia-Pacific Market size and forecast, by disease
7.4.11.3. Rest of Asia-Pacific Market size and forecast, by end user
7.5. LAMEA
7.5.1. Key market trendsand opportunities
7.5.2. Market size and forecast, by country
7.5.3. Market size and forecast, by Syringe Size
7.5.4. Market size and forecast, by disease
7.5.5. Market size and forecast, by end user
7.5.6. Brazil
7.5.6.1. Brazil Market size and forecast, by age group
7.5.6.2. Brazil Market size and forecast, by disease
7.5.6.3. Brazil Market size and forecast, by end user
7.5.7. Saudi Arabia
7.5.7.1. Saudi Arabia Market size and forecast, by Syringe Size
7.5.7.2. Saudi Arabia Market size and forecast, by Disease
7.5.7.3. Saudi Arabia Market size and forecast, by end user
7.5.8. South Africa
7.5.8.1. South Africa Market size and forecast, by Syringe Size
7.5.8.2. South Africa Market size and forecast, by Disease
7.5.8.3. South Africa Market size and forecast, by end user
7.5.9. Rest of LAMEA
7.5.9.1. Rest of LAMEA Market size and forecast, by Syringe Size
7.5.9.2. Rest of LAMEA Market size and forecast, by disease
7.5.9.3. Rest of LAMEA Market size and forecast, by end user

8.1. Abbott Laboratories
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.2. Biocon Ltd
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.3. Becton, Dickinson and Company
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.4. CARDINAL HEALTH
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.5. Eli Lily and Company
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.6. HINDUSTAN SYRINGES AND MEDICAL DEVICES LTD
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.7. Medline Industries
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.8. NIPRO MEDICAL CORPORATION
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.9. NOVO NORDISk
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.10. TERUMO CORPORATION
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance

TABLE 01. INSULIN SYRINGES MARKET, BY SYRINGE SIZE, 2020-2030 ($MILLION)
TABLE 02. INSULIN SYRINGES MARKET FOR 3/10 CC SYRINGES (0.3 ML), BY REGION, 2020-2030 ($MILLION)
TABLE 03. INSULIN SYRINGES MARKET FOR 1/2 CC SYRINGE (0.5 ML), BY REGION, 2020-2030 ($MILLION)
TABLE 04. INSULIN SYRINGES MARKET FOR 1CC SYRINGE (1 ML), BY REGION, 2020-2030 ($MILLION)
TABLE 05. INSULIN SYRINGES MARKET FOR OTHERS, BY REGION, 2020-2030 ($MILLION)
TABLE 06. INSULIN SYRINGES MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 07. INSULIN SYRINGES MARKET FOR TYPE-1 DIABETES, BY REGION, 2020-2030 ($MILLION)
TABLE 08. INSULIN SYRINGES MARKET FOR TYPE-2 DIABETES, BY REGION, 2020-2030 ($MILLION)
TABLE 09. INSULIN SYRINGES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 10. INSULIN SYRINGES MARKET FOR HOSPITAL& CLINICS, BY REGION, 2020-2030 ($MILLION)
TABLE 11. INSULIN SYRINGES MARKET FOR HOMECARE SETTINGS, BY REGION, 2020-2030 ($MILLION)
TABLE 12. INSULIN SYRINGES MARKET FOR OTHERS, BY REGION, 2020-2030 ($MILLION)
TABLE 13. INSULIN SYRINGES MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 14. NORTH AMERICA INSULIN SYRINGES MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 15. NORTH AMERICA INSULIN SYRINGES MARKET, BYSYRINGE SIZE, 2020-2030 ($MILLION)
TABLE 16. NORTH AMERICA INSULIN SYRINGES MARKET, BYDISEASE, 2020-2030 ($MILLION)
TABLE 17. NORTH AMERICA INSULIN SYRINGES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 18. U.S. INSULIN SYRINGES MARKET, BY SYRINGE SIZE, 2020-2030 ($MILLION)
TABLE 19. U.S. INSULIN SYRINGES MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 20. U.S. INSULIN SYRINGES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 21. CANADA INSULIN SYRINGES MARKET, BY SYRINGE SIZE, 2020-2030 ($MILLION)
TABLE 22. CANADAINSULIN SYRINGES MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 23. CANADA INSULIN SYRINGES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 24. MEXICO INSULIN SYRINGES MARKET, BY SYRINGE SIZE, 2020-2030 ($MILLION)
TABLE 25. MEXICO INSULIN SYRINGES MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 26. MEXICO INSULIN SYRINGES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 27. EUROPE INSULIN SYRINGES MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 28. EUROPE INSULIN SYRINGES MARKET, BY SYRINGE SIZE, 2020-2030 ($MILLION)
TABLE 29. EUROPE INSULIN SYRINGES MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 30. EUROPE INSULIN SYRINGES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 31. GERMANY INSULIN SYRINGES MARKET, BY SYRINGE SIZE, 2020-2030 ($MILLION)
TABLE 32. GERMANY INSULIN SYRINGES MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 33. GERMANY INSULIN SYRINGES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 34. FRANCE INSULIN SYRINGES MARKET, BY SYRINGE SIZE, 2020-2030 ($MILLION)
TABLE 35. FRANCEINSULIN SYRINGES MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 36. FRANCE INSULIN SYRINGES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 37. UK INSULIN SYRINGES MARKET, BY SYRINGE SIZE, 2020-2030 ($MILLION)
TABLE 38. UKINSULIN SYRINGES MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 39. UK INSULIN SYRINGES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 40. ITALY INSULIN SYRINGES MARKET, BY SYRINGE SIZE, 2020-2030 ($MILLION)
TABLE 41. ITALY INSULIN SYRINGES MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 42. ITALY INSULIN SYRINGES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 43. SPAIN INSULIN SYRINGES MARKET, BY SYRINGE SIZE, 2020-2030 ($MILLION)
TABLE 44. SPAININSULIN SYRINGES MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 45. SPAIN INSULIN SYRINGES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 46. REST OF EUROPE INSULIN SYRINGES MARKET, BY SYRINGE SIZE, 2020-2030 ($MILLION)
TABLE 47. REST OF EUROPEINSULIN SYRINGES MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 48. REST OF EUROPE INSULIN SYRINGES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 49. ASIA-PACIFIC INSULIN SYRINGES MARKET, BY COUNTRY, 2020-2030($MILLION)
TABLE 50. ASIA-PACIFIC INSULIN SYRINGES MARKET, BY SYRINGE SIZE, 2020-2030 ($MILLION)
TABLE 51. ASIA-PACIFIC INSULIN SYRINGES MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 52. ASIA-PACIFIC INSULIN SYRINGES MARKET, BY END USER, 2020-2030($MILLION)
TABLE 53. JAPAN INSULIN SYRINGES MARKET, BY SYRINGE SIZE, 2020-2030 ($MILLION)
TABLE 54. JAPAN INSULIN SYRINGES MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 55. JAPAN INSULIN SYRINGES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 56. CHINA INSULIN SYRINGES MARKET, BY SYRINGE SIZE, 2020-2030 ($MILLION)
TABLE 57. CHINA INSULIN SYRINGES MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 58. CHINA INSULIN SYRINGES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 59. AUSTRALIA INSULIN SYRINGES MARKET, BY SYRINGE SIZE, 2020-2030 ($MILLION)
TABLE 60. AUSTRALIAINSULIN SYRINGES MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 61. AUSTRALIA INSULIN SYRINGES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 62. INDIA INSULIN SYRINGES MARKET, BY SYRINGE SIZE, 2020-2030 ($MILLION)
TABLE 63. INDIAINSULIN SYRINGES MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 64. INDIA INSULIN SYRINGES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 65. SOUTH KOREA INSULIN SYRINGES MARKET, BY SYRINGE SIZE, 2020-2030 ($MILLION)
TABLE 66. SOUTH KOREAINSULIN SYRINGES MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 67. SOUTH KOREAINSULIN SYRINGES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 68. REST OF ASIA-PACIFIC INSULIN SYRINGES MARKET, BY SYRINGE SIZE, 2020-2030 ($MILLION)
TABLE 69. REST OF ASIA-PACIFICINSULIN SYRINGES MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 70. REST OF ASIA-PACIFIC INSULIN SYRINGES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 71. LAMEA INSULIN SYRINGES MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 72. LAMEA INSULIN SYRINGES MARKET, BY SYRINGE SIZE, 2020-2030 ($MILLION)
TABLE 73. LAMEA INSULIN SYRINGES MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 74. LAMEA INSULIN SYRINGES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 75. BRAZIL INSULIN SYRINGES MARKET, BY SYRINGE SIZE, 2020-2030 ($MILLION)
TABLE 76. BRAZILINSULIN SYRINGES MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 77. BRAZIL INSULIN SYRINGES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 78. SAUDI ARABIA INSULIN SYRINGES MARKET, BY SYRINGE SIZE, 2020-2030 ($MILLION)
TABLE 79. SAUDI ARABIAINSULIN SYRINGES MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 80. SAUDI ARABIA INSULIN SYRINGES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 81. SOUTH AFRICA INSULIN SYRINGES MARKET, BY SYRINGE SIZE, 2020-2030 ($MILLION)
TABLE 82. SOUTH AFRICAINSULIN SYRINGES MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 83. SOUTH AFRICA INSULIN SYRINGES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 84. REST OF LAMEA INSULIN SYRINGES MARKET, BY SYRINGE SIZE, 2020-2030 ($MILLION)
TABLE 85. REST OF LAMEAINSULIN SYRINGES MARKET, BY DISEASE, 2020-2030 ($MILLION)
TABLE 86. REST OF LAMEA INSULIN SYRINGES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 01. ABBOTT: COMPANY SNAPSHOT
TABLE 02. ABBOTT: OPERATING SEGMENTS
TABLE 03. ABBOTT: PRODUCT PORTFOLIO
TABLE 04. BIOCON: COMPANY SNAPSHOT
TABLE 05. BIOCON: OPERATING SEGMENTS
TABLE 06. BIOCON: PRODUCT PORTFOLIO
TABLE 07. BD: COMPANY SNAPSHOT
TABLE 08. BD: OPERATING SEGMENTS
TABLE 09. BD: PRODUCT PORTFOLIO
TABLE 10. CARDINAL HEALTH: COMPANY SNAPSHOT
TABLE 11. CARDINAL HEALTH: OPERATING SEGMENT
TABLE 12. CARDINAL HEALTH: PRODUCT PORTFOLIO
TABLE 13. ELI LILLY: COMPANY SNAPSHOT
TABLE 14. ELI LILLY: OPERATING SEGMENTS
TABLE 15. ELI LILLY: PRODUCT PORTFOLIO
TABLE 16. HMD: COMPANY SNAPSHOT
TABLE 17. HMD: OPERATING SEGMENTS
TABLE 18. HMD: PRODUCT PORTFOLIO:
TABLE 19. MEDLINE: COMPANY SNAPSHOT
TABLE 20. MEDLINE: OPERATING SEGMENTS
TABLE 21. MEDLINE: PRODUCT PORTFOLIO
TABLE 22. NIPRO: COMPANY SNAPSHOT
TABLE 23. NIPRO: OPERATING SEGMENTS
TABLE 24. NIPRO: PRODUCT PORTFOLIO:
TABLE 25. NOVO NORDISK: COMPANY SNAPSHOT
TABLE 26. NOVO NORDISK: OPERATING SEGMENTS
TABLE 27. NOVO NORDISK: PRODUCT PORTFOLIO
TABLE 28. TERUMO: COMPANY SNAPSHOT
TABLE 29. TERUMO CORPORATION: PRODUCT SEGMENTS
TABLE 30. TERUMO: PRODUCT PORTFOLIO

FIGURE 01. INSULIN SYRINGES MARKET SEGMENTATION
FIGURE 02. TOP PLAYER POSITIONING, 2020
FIGURE 03. TOP INVESTMENT POCKETS
FIGURE 04. HIGH BARGAINING POWER OF SUPPLIER
FIGURE 05. MODERATEBARGAINING POWER OF BUYERS
FIGURE 06. MODERATE THREAT OF SUBSTITUTES
FIGURE 07. HIGH INTENSITY OF RIVALRY
FIGURE 08. HIGH THREAT OF NEW ENTRANT
FIGURE 09. IMPACT ANALYSES, INSULIN SYRINGES MARKET
FIGURE 10. COMPARATIVE ANALYSIS OF INSULIN SYRINGES MARKET FOR 3/10 CC SYRINGES (0.3 ML), BY COUNTRY, 2020 & 2030 (%)
FIGURE 11. COMPARATIVE ANALYSIS OF INSULIN SYRINGES MARKET FOR 1/2 CC SYRINGE (0.5 ML), BY COUNTRY, 2020 & 2030 (%)
FIGURE 12. COMPARATIVE ANALYSIS OF INSULIN SYRINGES MARKET FOR 1CC SYRINGE (1 ML), BY COUNTRY, 2020 & 2030 (%)
FIGURE 13. COMPARATIVE ANALYSIS OF INSULIN SYRINGES MARKET FOR OTHERS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 14. COMPARATIVE ANALYSIS OF INSULIN SYRINGES MARKET FOR TYPE-1 DIABETES, BY COUNTRY, 2020 & 2030 (%)
FIGURE 15. COMPARATIVE ANALYSIS OF INSULIN SYRINGES MARKET FOR TYPE-2 DIABETES, BY COUNTRY, 2020 & 2030 (%)
FIGURE 16. COMPARATIVE ANALYSIS OF INSULIN SYRINGES MARKET FOR HOSPITALS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 17. COMPARATIVE ANALYSIS OF INSULIN SYRINGES MARKET FOR HOMECARE SETTINGS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 18. COMPARATIVE ANALYSIS OF INSULIN SYRINGES MARKET FOR OTHERS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 01. ABBOTT: NET SALES, 2018-2020 ($MILLION)
FIGURE 02. ABBOTT: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 03. ABBOTT: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 04. BIOCON: NET SALES, 2018-2020 ($MILLION)
FIGURE 05. BIOCON: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 06. BIOCON: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 07. BD: NET SALES, 2018-2020 ($MILLION)
FIGURE 08. BD: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 09. BD: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 10. CARDINAL HEALTH: NET SALES, 2018-2020 ($MILLION)
FIGURE 11. CARDINAL HEALTH: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 12. CARDINAL HEALTH: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 13. NET SALES, 2018-2020 ($MILLION)
FIGURE 14. ELI LILLY REVENUE SHARE BY BUSINESS UNIT, 2020 (%)
FIGURE 15. ELI LILLY: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 16. NIPRO: NET SALES, 2018-2020 ($MILLION)
FIGURE 17. NIPRO: REVENUE SHARE BY SEGMENTS, 2020 (%)
FIGURE 18. NIPRO: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 19. NET SALES, 2018-2020 ($MILLION)
FIGURE 20. NOVO NORDISK: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 21. NOVO NORDISK: REVENUE SHARE BY GEOGRAPHY, 2020 (%)
FIGURE 22. TERUMO: NET SALES, 2017-2019 ($MILLION)
FIGURE 23. TERUMO: REVENUE SHARE BY SEGMENTS, 2019 (%)
FIGURE 24. TERUMO: REVENUE SHARE BY REGION, 2019 (%)